SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

Slieve Russell Hotel has demonstrated a remarkable commitment to its people by creating a culture that prioritises ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...

Join Open Class Action Against AbbVie CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of ...

AbbVie Inc. closed 0.64% short of its 52-week high of $215.66, which the company reached on March 4th.

NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate ...

Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...